RxDoctor Payments Data

Thomas Coss

Physician Assistant · Elmira, NYNPI 1356440473

Payments from drug & device makers

$756in general payments, 2019–2025

Across 38 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$251
  • Merck$147
  • Novo Nordisk$101
  • AstraZeneca$83
  • Pfizer$73
  • Johnson & Johnson$52
  • plus $51 from 2 others

What the payments were for

  • Food & beverage$756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie10$251
Merck8$147
Novo Nordisk6$101
AstraZeneca5$83
Pfizer4$73
Johnson & Johnson3$52
Amgen1$29
Boehringer Ingelheim1$22

How this compares

$756 in reported general payments places this provider in the 70th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$65,996
Medicare patients
253
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$287,660
OzempicSemaglutide95$97,325
JardianceEmpagliflozin50$62,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$59,912
XareltoRivaroxaban29$48,537
JanuviaSitagliptin Phosphate20$26,126
EntrestoSacubitril/Valsartan17$21,067
OxycontinOxycodone Hcl22$17,771
BrilintaTicagrelor18$15,922
JanumetSitagliptin Phos/Metformin Hcl11$14,508
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$13,269
Potassium Chloride321$11,531
Atorvastatin Calcium930$8,644
Spiriva RespimatTiotropium Bromide11$7,873
Metoprolol Succinate426$7,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$287,660226 claims
Novo NordiskOzempic$101$97,32595 claims
Boehringer IngelheimJardiance, Spiriva Respimat$22$70,18461 claims
Johnson & JohnsonXarelto$52$48,53729 claims
MerckJanuvia, Janumet$147$40,63431 claims
AstraZenecaBrilinta, Symbicort$83$22,94030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →